Selank

Overview

Selank is a synthetic peptide developed in Russia, designed as a stable analog of a naturally occurring immune fragment called tuftsin. It is studied mainly as an anxiolytic (anti-anxiety) and nootropic agent, and is typically administered as an intranasal spray. In Russia it has been used clinically for generalized anxiety, but it has no comparable status elsewhere.

Selank is not approved by the FDA or most Western regulators, and in those markets it circulates largely as a research chemical. Interest in it comes from reports that it may reduce anxiety without the sedation, dependence, or withdrawal associated with conventional benzodiazepines, though this comparison rests on limited data.

As with many peptides emerging from the Russian research tradition, the published literature is real but relatively small and not widely replicated by independent Western groups. Selank is best understood as an investigational compound with intriguing properties rather than an established treatment, and consumer products vary widely in quality and verification.

How it works

Selank's mechanisms are still being mapped, but research points to several overlapping pathways. It appears to influence the GABAergic system, the brain's primary inhibitory network, which is also the target of traditional anti-anxiety drugs. By modulating this system, Selank may promote a calmer state without the heavy sedation typical of benzodiazepines.

It has also been reported to affect levels of brain-derived neurotrophic factor and the expression of genes related to neuroplasticity, as well as monoamine neurotransmitters such as serotonin and dopamine. These effects are proposed to underlie its nootropic, mood-stabilizing reputation. Additionally, as a tuftsin analog, Selank retains some immune-modulating and anti-inflammatory activity.

Because it is derived from tuftsin and resists rapid breakdown, Selank is thought to act more durably than the natural fragment. However, the precise sequence of molecular events linking these various effects to its behavioral results is not fully established, and much of the mechanistic work comes from animal models rather than detailed human studies.

Research & evidence

Most published research on Selank originates from Russian laboratories and clinical groups. These studies, including some human trials, suggest it can reduce anxiety symptoms and may support attention and memory, sometimes comparing favorably to standard anxiolytics on tolerability. Animal research has explored its effects on stress, learning, and inflammation.

The major limitation is that this body of evidence has not been broadly replicated by independent international teams, and many studies are small or methodologically limited by modern standards. Large, rigorously controlled trials of the kind required for regulatory approval in the United States or Europe have not been published.

As a result, claims about Selank's benefits should be read as preliminary. The compound is plausible and interesting, and the early data are encouraging, but the gap between promising Russian-language research and globally accepted clinical proof remains significant. Consumers should not interpret its use abroad as equivalent to validated, approved efficacy.

Safety & legal status

Selank is not FDA-approved and is not a recognized medicine in most Western countries; in those markets it is generally sold as a research chemical not intended for human consumption. Its legal status varies, and purchasing it does not guarantee identity, purity, or sterility of the product received.

Reported tolerability in the available literature is relatively favorable, with the appeal partly being a lack of the dependence and sedation seen with benzodiazepines. However, the absence of large long-term safety studies means that rare or delayed adverse effects cannot be ruled out, and intranasal products carry their own local irritation and contamination considerations.

This information is educational and is not medical advice or a dosing protocol. Anxiety is a serious medical condition with proven, regulated treatments, and anyone struggling should seek care from a licensed clinician rather than self-treating with an unapproved peptide of uncertain provenance.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and mechanisms of action of the peptide anxiolytic selank in generalized anxiety disorder and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. Peer-reviewed study
2. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating BDNF. Bull Exp Biol Med. 2019. Peer-reviewed study
3. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022. Peer-reviewed study
4. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017. Peer-reviewed study
5. Vyunova TV, Andreeva L, Shevchenko K, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018. Peer-reviewed study
6. Fomenko EV, Bobyntsev II, Ivanov AV, et al. Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Bull Exp Biol Med. 2019. Peer-reviewed study